CA2199954A1 - Spray-dried microparticles as therapeutic vehicles - Google Patents
Spray-dried microparticles as therapeutic vehiclesInfo
- Publication number
- CA2199954A1 CA2199954A1 CA002199954A CA2199954A CA2199954A1 CA 2199954 A1 CA2199954 A1 CA 2199954A1 CA 002199954 A CA002199954 A CA 002199954A CA 2199954 A CA2199954 A CA 2199954A CA 2199954 A1 CA2199954 A1 CA 2199954A1
- Authority
- CA
- Canada
- Prior art keywords
- microparticles
- microparticles according
- water
- soluble material
- microcapsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011859 microparticle Substances 0.000 title claims abstract description 64
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 11
- 239000002245 particle Substances 0.000 claims abstract description 77
- 239000003814 drug Substances 0.000 claims abstract description 50
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 17
- 239000002195 soluble material Substances 0.000 claims abstract description 13
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 8
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 8
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 49
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 30
- 238000001694 spray drying Methods 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000003839 Human Proteins Human genes 0.000 claims description 3
- 108090000144 Human Proteins Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000002198 insoluble material Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 22
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003094 microcapsule Substances 0.000 description 71
- 229940079593 drug Drugs 0.000 description 30
- 239000000203 mixture Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000463 material Substances 0.000 description 24
- 102000009027 Albumins Human genes 0.000 description 18
- 108010088751 Albumins Proteins 0.000 description 18
- 239000004005 microsphere Substances 0.000 description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 17
- 239000008101 lactose Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 229940112141 dry powder inhaler Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000004472 Lysine Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical class CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000012798 spherical particle Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 6
- 238000000889 atomisation Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229960002052 salbutamol Drugs 0.000 description 6
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 229960004436 budesonide Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229940092705 beclomethasone Drugs 0.000 description 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000007431 microscopic evaluation Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- MTNMEPVEOOIECV-UHFFFAOYSA-N 1,2-dimethyl-3,4-diphenylbenzene Chemical compound C=1C=CC=CC=1C1=C(C)C(C)=CC=C1C1=CC=CC=C1 MTNMEPVEOOIECV-UHFFFAOYSA-N 0.000 description 3
- 235000021357 Behenic acid Nutrition 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000002961 echo contrast media Substances 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- -1 tert-butyloxy-carbonylmethyl Chemical group 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000000708 deep reactive-ion etching Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000009549 lung scintigraphy Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000013385 tryptic peptide mapping Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Radiology & Medical Imaging (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94307126.6 | 1994-09-29 | ||
| EP94307126 | 1994-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2199954A1 true CA2199954A1 (en) | 1996-04-04 |
Family
ID=8217866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002199954A Abandoned CA2199954A1 (en) | 1994-09-29 | 1995-09-26 | Spray-dried microparticles as therapeutic vehicles |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0783298A1 (fi) |
| JP (1) | JPH10506406A (fi) |
| KR (1) | KR970705979A (fi) |
| AU (1) | AU701440B2 (fi) |
| BR (1) | BR9509171A (fi) |
| CA (1) | CA2199954A1 (fi) |
| CZ (1) | CZ92497A3 (fi) |
| FI (1) | FI971332A (fi) |
| HU (1) | HUT77373A (fi) |
| MX (1) | MX9702357A (fi) |
| NO (1) | NO971438L (fi) |
| NZ (1) | NZ292980A (fi) |
| PL (1) | PL319600A1 (fi) |
| RU (1) | RU2147226C1 (fi) |
| WO (1) | WO1996009814A1 (fi) |
| ZA (1) | ZA958239B (fi) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9827205B2 (en) | 2008-12-12 | 2017-11-28 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5955108A (en) * | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
| GB9607035D0 (en) * | 1996-04-03 | 1996-06-05 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
| EP0914096B1 (en) * | 1996-05-17 | 2003-08-13 | Elan Drug Delivery Limited | Microparticles and their use in wound therapy |
| GB9610341D0 (en) * | 1996-05-17 | 1996-07-24 | Andaris Ltd | Formulation for inhalation |
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| GB9615435D0 (en) * | 1996-07-23 | 1996-09-04 | Andaris Ltd | Spray-dried product and its therapeutic use |
| GB9621825D0 (en) * | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
| WO1998017318A1 (en) * | 1996-10-19 | 1998-04-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules in diagnosis and therapy |
| US5976574A (en) * | 1996-12-31 | 1999-11-02 | Inhale Therapeutic Systems | Processes for spray drying hydrophobic drugs in organic solvent suspensions |
| EP1498115A1 (en) * | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| CA2277801C (en) * | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| EP1019020A1 (en) † | 1997-09-29 | 2000-07-19 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| GB9727102D0 (en) * | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
| WO1999042146A1 (en) * | 1998-02-20 | 1999-08-26 | Quadrant Healthcare (Uk) Limited | Products comprising fibrinogen for use in therapy |
| EP1273290A1 (en) * | 1998-06-24 | 2003-01-08 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| WO1999066903A2 (en) * | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| ATE289825T1 (de) * | 1999-04-21 | 2005-03-15 | 1355540 Ontario Inc | Methacoline oder histamine formulierungen zur feststellung von asthma |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| JP2003518038A (ja) | 1999-12-20 | 2003-06-03 | ニコラス， ジェイ カークホフ， | 流動床噴霧乾燥によるナノ粒子製造方法 |
| US8771740B2 (en) * | 1999-12-20 | 2014-07-08 | Nicholas J. Kerkhof | Process for producing nanoparticles by spray drying |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| WO2001093837A2 (en) * | 2000-06-08 | 2001-12-13 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| DE60127175T2 (de) | 2000-12-21 | 2007-11-08 | Nektar Therapeutics, San Carlos | Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor |
| GB0111420D0 (en) * | 2001-05-10 | 2001-07-04 | Biovector Solutions Ltd | Soluble polymer systems for drug delivery |
| DE60227691D1 (de) | 2001-11-01 | 2008-08-28 | Nektar Therapeutics | Sprühtrocknungsverfahren |
| CA2468958C (en) | 2001-12-19 | 2012-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
| US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
| DK2526996T3 (da) | 2002-12-20 | 2019-12-02 | Xeris Pharmaceuticals Inc | Formulering til intrakutan injektion |
| EP1635786A2 (en) | 2003-05-28 | 2006-03-22 | Nektar Therapeutics | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
| CN1826170B (zh) | 2003-07-18 | 2010-12-08 | 巴克斯特国际公司 | 通过受控相分离制备的小球形颗粒的制造方法、其用途和成分 |
| DE10339197A1 (de) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| AU2005244840C1 (en) | 2004-05-12 | 2012-05-10 | Baxter Healthcare S.A. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
| EP3590503A1 (en) | 2006-10-12 | 2020-01-08 | The University of Queensland | Compositions and methods for modulating immune responses |
| EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| UA90013C2 (ru) * | 2008-03-19 | 2010-03-25 | Давид Анатолійович Нога | Фармацевтическая композиция, содержащая инсулин, и способ его получения |
| US11524058B2 (en) | 2008-09-29 | 2022-12-13 | The Corporation Of Mercer University | Oral dissolving films containing microencapsulated vaccines and methods of making same |
| US10004790B2 (en) | 2008-09-29 | 2018-06-26 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| US10463608B2 (en) | 2008-09-29 | 2019-11-05 | The Corporation Of Mercer University | Microneedle-based transdermal delivery system and method of making same |
| WO2010037142A1 (en) * | 2008-09-29 | 2010-04-01 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| EP2216054A1 (en) | 2009-02-06 | 2010-08-11 | ProFibrix BV | Biodegradable extravascular support |
| PL2435028T3 (pl) * | 2009-05-28 | 2017-09-29 | Profibrix Bv | Uszczelniacz fibrynowy w postaci suchego proszku |
| GB0909136D0 (en) | 2009-05-28 | 2009-07-01 | Profibrix Bv | Dry powder composition |
| GB0909131D0 (en) | 2009-05-28 | 2009-07-01 | Quadrant Drug Delivery Ltd | Dry powder fibrin sealant |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| KR20120125465A (ko) | 2010-01-08 | 2012-11-15 | 프로피브릭스 비.브이. | 건조 분말 피브린 실란트 |
| WO2012012460A1 (en) | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
| DK2635596T3 (da) | 2010-11-01 | 2019-11-25 | Univ Sydney Technology | Immun-moduleringsmidler og anvendelser dertil |
| CN103442695B (zh) | 2011-03-10 | 2016-05-04 | Xeris药物公司 | 肠胃外注射用肽药物的稳定制剂 |
| EP3225235B1 (en) | 2011-03-10 | 2020-12-16 | Xeris Pharmaceuticals, Inc. | Stable peptide formulations for parenteral injection |
| RU2013155713A (ru) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
| CA2853942C (en) | 2011-10-31 | 2020-08-25 | Xeris Pharmaceuticals, Inc. | Formulations for the treatment of diabetes |
| US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
| KR102139393B1 (ko) * | 2012-06-26 | 2020-07-29 | 지이 헬스케어 에이에스 | 기체 미세기포를 포함하는 조성물의 제조 |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| CN105163735B (zh) | 2013-02-01 | 2018-12-11 | 格力尔罗格克斯股份有限公司 | 用于治疗神经退行性疾病和其他疾病的组合物和方法 |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| WO2014124096A1 (en) | 2013-02-06 | 2014-08-14 | Perosphere Inc. | Stable glucagon formulations |
| RU2707285C2 (ru) | 2013-10-08 | 2019-11-26 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Рапамицин для лечения лимфангиолейомиоматоза |
| HRP20230863T1 (hr) | 2014-04-04 | 2023-11-10 | AI Therapeutics, Inc. | Inhalacijska formulacija rapamicina, namijenjena liječenju stanja povezanih sa starenjem |
| EP4198059A1 (en) | 2014-05-27 | 2023-06-21 | The University of Queensland | Modulation of cellular stress |
| AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
| EP3209330B1 (en) | 2014-10-07 | 2022-02-23 | AI Therapeutics, Inc. | An inhalable sirolimus formulation for the treatment of pulmonary hypertension |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| WO2016196976A1 (en) | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
| EP3307295A1 (en) | 2015-06-10 | 2018-04-18 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
| US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
| WO2017062463A1 (en) | 2015-10-05 | 2017-04-13 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| US11628208B2 (en) | 2015-10-05 | 2023-04-18 | The Corporation Of Mercer University | System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins |
| US20180110760A1 (en) | 2016-10-21 | 2018-04-26 | Glialogix, Inc. | Compositions and methods for the treatmentof neurodegenerative and other diseases |
| CN117085022A (zh) | 2017-06-02 | 2023-11-21 | Xeris药物公司 | 抗沉淀的小分子药物制剂 |
| WO2021090214A2 (en) * | 2019-11-04 | 2021-05-14 | Alesco S.R.L. | Sucrosomial® berberine, its compositions and their use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626871A (en) * | 1992-06-12 | 1997-05-06 | Teijin Limited | Preparation for intratracheobronchial administration |
| CA2115065C (en) * | 1992-06-12 | 2000-10-03 | Kiyoyuki Sakon | Ultrafine particle powder for inhalation and method for production thereof |
-
1995
- 1995-09-26 KR KR1019970702043A patent/KR970705979A/ko not_active Application Discontinuation
- 1995-09-26 AU AU35302/95A patent/AU701440B2/en not_active Ceased
- 1995-09-26 WO PCT/GB1995/002279 patent/WO1996009814A1/en not_active Application Discontinuation
- 1995-09-26 RU RU97106769A patent/RU2147226C1/ru not_active IP Right Cessation
- 1995-09-26 CA CA002199954A patent/CA2199954A1/en not_active Abandoned
- 1995-09-26 EP EP95932122A patent/EP0783298A1/en not_active Ceased
- 1995-09-26 MX MX9702357A patent/MX9702357A/es unknown
- 1995-09-26 BR BR9509171A patent/BR9509171A/pt not_active Application Discontinuation
- 1995-09-26 JP JP8511495A patent/JPH10506406A/ja not_active Ceased
- 1995-09-26 NZ NZ292980A patent/NZ292980A/xx not_active IP Right Cessation
- 1995-09-26 CZ CZ97924A patent/CZ92497A3/cs unknown
- 1995-09-26 PL PL95319600A patent/PL319600A1/xx unknown
- 1995-09-26 HU HU9702161A patent/HUT77373A/hu unknown
- 1995-09-29 ZA ZA958239A patent/ZA958239B/xx unknown
-
1997
- 1997-03-26 NO NO971438A patent/NO971438L/no not_active Application Discontinuation
- 1997-04-01 FI FI971332A patent/FI971332A/fi not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9827205B2 (en) | 2008-12-12 | 2017-11-28 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
Also Published As
| Publication number | Publication date |
|---|---|
| AU701440B2 (en) | 1999-01-28 |
| WO1996009814A1 (en) | 1996-04-04 |
| AU3530295A (en) | 1996-04-19 |
| CZ92497A3 (en) | 1997-08-13 |
| JPH10506406A (ja) | 1998-06-23 |
| BR9509171A (pt) | 1997-09-16 |
| HUT77373A (hu) | 1998-03-30 |
| ZA958239B (en) | 1996-09-30 |
| KR970705979A (ko) | 1997-11-03 |
| PL319600A1 (en) | 1997-08-18 |
| NO971438D0 (no) | 1997-03-26 |
| RU2147226C1 (ru) | 2000-04-10 |
| FI971332A0 (fi) | 1997-04-01 |
| MX9702357A (es) | 1997-06-28 |
| FI971332A (fi) | 1997-04-01 |
| NZ292980A (en) | 1999-02-25 |
| NO971438L (no) | 1997-03-26 |
| EP0783298A1 (en) | 1997-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU701440B2 (en) | Spray-dried microparticles as therapeutic vehicles | |
| US5993805A (en) | Spray-dried microparticles and their use as therapeutic vehicles | |
| MXPA97002357A (en) | Microparticles dried by aspersion as vehicles therapeuti | |
| US6416739B1 (en) | Microparticles and their therapeutic or diagnostic use | |
| JP4416325B2 (ja) | 安定な噴霧乾燥タンパク質製剤 | |
| CA2216828C (en) | Controlled release insufflation carrier for medicaments | |
| US5707644A (en) | Small particle compositions for intranasal drug delivery | |
| DE69907456T2 (de) | Grosse poröse partikel ausgestossen von einem inhalator | |
| CA2277801C (en) | Preparation of particles for inhalation | |
| CN101090714A (zh) | 通过吸入伊洛前列素和微粒制剂治疗肺动脉高血压症 | |
| JP2006503865A (ja) | 吸入のための徐放性の多孔性微粒子 | |
| JP2002524535A (ja) | 乾燥粉末活性薬剤肺性送達 | |
| KR20020060218A (ko) | 개선된 분산성을 갖는 건조 분말 조성물 | |
| CN1164186A (zh) | 用作治疗载体的经喷雾干燥的微颗粒 | |
| MXPA01002649A (en) | Dry powder active agent pulmonary delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |